MTI
LGND icon

Merrithew & Thorsten Inc’s Ligand Pharmaceuticals LGND Stock Holding History

Merrithew & Thorsten Inc’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40K Hold
129
– – 0.03% 50
2026
Q1 		$25K Hold
129
– – 0.02% 58
2025
Q4 		$24K Buy
+129
New +$24.8K 0.03% 56

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Merrithew & Thorsten Inc's LGND Position: Q2 2026 in Review

Merrithew & Thorsten Inc held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 129 shares worth $40K. The position accounts for 0.03% of the portfolio, ranked #50.

Merrithew & Thorsten Inc first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Merrithew & Thorsten Inc held 129 shares of Ligand Pharmaceuticals worth $40K as of Q2 2026.
  • Merrithew & Thorsten Inc left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 0.03% of Merrithew & Thorsten Inc's portfolio in Q2 2026, its #50 holding.
  • Merrithew & Thorsten Inc first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Merrithew & Thorsten Inc's 13F filing for Q2 2026, filed 31 Jul 2026.